Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Summary

The aim of this study is rate of acute graft-versus-host disease II-IV measured at day +365according to conventional criteria (Przepiorka et al. 1995) in patients with high risk non-Hodgkin lymphoma B subjects with Allogeneic Stem Cell Transplant

Timeline

Start

2012-04-04

Primary completion

2016-06

Completion

2020-06

Publications

• Cabrero M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, Perez-Lopez E, Valcarcel D, Sanz J, Espigado I, Orti G, Martin-Calvo C, de la Serna J, Caballero D; Grupo Espanol de Trasplante Hematopoyetico (GETH) and Grupo Espanol de Linfomas y Trasplante Autologo (GELTAMO). Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2.

Drugs

Indications